Revvityvs.Waters Corporation
RVTY vs WAT · both in Life science tools, part of the Medicine, pharma & life science value chain: Instruments, reagents and equipment for research, development and production.
Waters Corporation is about 2.5× larger than Revvity by market cap; Revvity trades at the lower P/E (72.6 vs 255.2); year to date, Revvity leads (+57.3% vs +13.0%).
Side by side
| RVTY | WAT | |
|---|---|---|
| Market cap | $17.2B | $42.4B |
| Price | $154.18 | $433.77 |
| Today | +1.3% | +1.1% |
| Return YTD | +57.3% | +13.0% |
| Return 1Y | +65.8% | +31.0% |
| Since June 26, 2026 | +36.4% | +15.9% |
| P/E | 72.6 | 255.2 |
| P/S | 5.9 | 9.1 |
| P/B | 2.4 | 2.8 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
RevvityRVTY
Newborn and genetic screening is the clinical end of the business; the rest supplies reagents and software to research laboratories.
Full RVTY profile →Waters CorporationWAT
Waters sells liquid chromatography and mass spectrometry systems; pharmaceutical companies and other laboratories buy them along with the consumables and software that keep them running.
Full WAT profile →More RVTY & WAT comparisons
Other head-to-heads in the Life science tools segment.